VETALOG INJ 6MG/ML
In Stock
Vetalog 6mg/ml Triamcinolone Acetonide Injection, manufactured by Zydus Animal Health and Investments Limited (Zydus AHL), is a prescription-only, parenteral veterinary corticosteroid formulated to address a broad spectrum of inflammatory, allergic, dermatological, and musculoskeletal conditions in dogs, cats, horses, cattle, sheep, goats, and other livestock. Inflammation, whether driven by immune hypersensitivity, autoimmune dysregulation, traumatic joint injury, or systemic metabolic crisis, represents one of the most clinically significant drivers of pain, tissue damage, and compromised animal welfare encountered in veterinary practice. Conventional corticosteroids at equivalent doses often carry disproportionate risks of sodium retention and fluid accumulation. Vetalog addresses this limitation directly by delivering Triamcinolone Acetonide, a highly potent synthetic glucocorticoid estimated to be 4 to 10 times more potent than hydrocortisone on a weight-for-weight basis, yet with markedly weaker mineralocorticoid activity, making it one of the most targeted and clinically precise anti-inflammatory agents available in veterinary medicine today. Each millilitre of the sterile suspension provides 6mg of Triamcinolone Acetonide with 0.9% benzyl alcohol as a preservative, carboxymethylcellulose sodium, polysorbate 80, and sodium chloride for isotonicity, formulated under nitrogen-replaced conditions for maximum stability. Animeal is proud to offer Vetalog 6mg/ml Triamcinolone Acetonide Injection as part of our curated range of clinically validated prescription veterinary pharmaceuticals.
Ingredients:
Triamcinolone Acetonide IP (6mg per mL): Triamcinolone Acetonide (C24H31FO6) is a fluorinated synthetic glucocorticoid of the 9-alpha-fluoro-16-alpha-hydroxy prednisolone family. At the molecular level, it exerts its primary therapeutic action by binding to intracellular glucocorticoid receptors (GRs) in target tissues. The drug-receptor complex translocates to the nucleus and acts as a transcription factor, upregulating anti-inflammatory proteins such as lipocortin-1 (annexin A1) and simultaneously downregulating the expression of pro-inflammatory cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and interferon-gamma. This dual genomic action suppresses the entire arachidonic acid inflammatory cascade by inhibiting phospholipase A2, thereby preventing the generation of both prostaglandins and leukotrienes. At the cellular level, Triamcinolone Acetonide stabilises lysosomal and mast cell membranes, reduces vascular permeability, inhibits leucocyte migration into inflamed tissue, and suppresses fibroblast proliferation, collectively alleviating oedema, erythema, pruritus, and pain within 24 hours of administration. The acetonide ester modification confers a higher lipid-water distribution coefficient compared to unesterified triamcinolone, enabling prolonged tissue retention and an extended duration of action of 7 to 15 days following intramuscular or subcutaneous administration, and up to 6 weeks following intramuscular injection in certain indications. In contrast to older corticosteroids, Triamcinolone Acetonide demonstrates minimal sodium-retaining (mineralocorticoid) activity, significantly reducing the risk of iatrogenic oedema and electrolyte disturbances at therapeutic doses.
Benzyl Alcohol IP (0.9% w/v) as Preservative: Benzyl alcohol functions as an antimicrobial preservative that prevents microbial contamination of the multi-dose vial between administrations. It inhibits microbial growth by disrupting cell membrane integrity in bacteria and fungi, ensuring sterility and product safety across the vial's in-use period. At the concentrations used, it also provides a mild local anaesthetic effect at the injection site.
Carboxymethylcellulose Sodium (0.75%): A hydrophilic polymer that serves as a suspending agent, maintaining the uniform dispersion of Triamcinolone Acetonide microcrystals throughout the aqueous vehicle. This controlled suspension technology regulates the rate of drug dissolution at the injection depot, directly contributing to the extended duration of action by ensuring a gradual, sustained release of the active molecule into the systemic circulation.
Polysorbate 80 (0.04%) A non-ionic surfactant that acts as a wetting and emulsifying agent, enhancing the fine and homogenous dispersion of drug particles within the suspension, improving injectability, and preventing particle agglomeration that could otherwise lead to uneven dosing.
Sodium Chloride: Included for isotonicity, ensuring that the injection formulation closely matches the physiological osmolality of blood and tissue fluids to minimise injection site discomfort and prevent cellular disruption at the site of administration.
Water for Injection IP: Pharmaceutical-grade sterile water serves as the aqueous base of the suspension, manufactured to IP specifications for parenteral use.
